Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

58.53 +1.64 (+2.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ↗
Via Chartmill
News headline image
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
Exelixis (NASDAQ:EXEL) Shows Strong Breakout Setup with Perfect Technical Rating ↗
Via Chartmill
Exelixis (NASDAQ:EXEL) Posts Mixed Q2: EPS Beats, Revenue Misses, Guidance Lowered ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL): A Decent Value Play in the Biotechnology Sector ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health ↗
Via Chartmill
News headline image
Exelixis (EXEL) Q2 2026 Earnings Call Transcript ↗
Cabozantinib revenue grew 10%, while zanzalintinib advances toward FDA decision in December. 
Via The Motley Fool
Topics Earnings
News headline image
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Exelixis Q2 Earnings Call Highlights ↗
Exelixis (NASDAQ:EXEL) reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential... 
Via MarketBeat
Topics Earnings
EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Case for Value Investors ↗
Via Chartmill
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
Via Chartmill
News headline image
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
They are riding strong tailwinds that could lift them higher. 
Via The Motley Fool
Topics Economy
News headline image
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
3 Under-the-Radar Stocks to Buy and Hold ↗
Sometimes, little-known stocks are worth buying. 
Via The Motley Fool
News headline image
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president... 
Via MarketBeat
News headline image
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
From Exelixis, Inc.
Via Business Wire
News headline image
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal ↗
NCR Atleos delivers self-service banking technology and managed services to financial institutions and enterprise clients worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Prediction: This Stock Could Double By 2031 ↗
It's not the most prominent company in its industry, but it is definitely worth a second look. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
Exelixis (EXEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.